For some years, there has been a perceived need for more information on the effect of screening for breast cancer in women aged 40 to 49. Our approach was to gather the most recent data on screening in this age group, to assess the following quantities: the likely beneffi in mortality terms, measure
Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancer
✍ Scribed by Ankit Bharat; Rebecca L. Aft; Feng Gao; Julie A. Margenthaler
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 72 KB
- Volume
- 100
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
The goal of the current study is to identify predictors responsible for mortality disparities between young (≤40 years) and older (>40 years) women with breast cancer.
Methods
From 1998 to 2006, 344 patients ≤40 years were treated for breast cancer. Cox regression models calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) to determine differences in breast cancer mortality in women ≤40 years versus >40 years (n = 3,252), controlling for potential confounders in univariate tests.
Results
From 1998 to 2006, 3,596 patients were treated for breast cancer; 9.6% were ≤40 years and 90.4% were >40 years. Young women were more likely to be African‐American, with a family history of breast cancer, diagnosed at advanced stage, and treated by mastectomy (P < 0.05). Tumors in young women were more likely to be bilateral, T2/T3, grade III, ER/PR negative, and lymph‐node positive (P < 0.01). Overall, young women (≤40 years) with breast cancer were more likely to die compared with older women (>40 years) (aHR 1.52, CI 1.37–1.74).
Conclusions
Young women (≤40 years) with breast cancer are diagnosed at a more advanced stage and have tumors with poor prognostic features. Young women (≤40 years) are 52% more likely to die from breast cancer compared to older women (>40 years). J. Surg. Oncol. 2009;100:248–251. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Somatic mutations in the TP53 gene are the most frequently observed genetic alterations in human malignancies, including breast cancer, which is one of the leading causes of death among women in Brazil. In our study, we determined the frequency and the pattern of TP53 mutations in malignant breast t